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1. Introduction
1.1. Inflammatory process of tuberculosis
When many infectious units of 1-3 bacilli are inhaled, a phenotypically hardy bacillus is likely
to be among them. In addition, the alveolar macrophages apparently vary in their capacity to
destroy bacilli [1]. Staining for acid-fast bacilli is very useful for demonstrating M. tuberculo‐
sis (A). Fig. 1 reveals histologic manifestation of tuberculosis over the time course. Histologi‐
cally, tuberculosis displays exudative inflammation (B), proliferative inflammation (D) and
productive inflammation (C) depending on the time course. Using animal experiments and an
inhalation exposure system, the pathologic condition of the infected animals was followed up
for one year. Exudative inflammation was observed for the first 10 days. Thereafter, granulo‐
mas, which corresponded to foci of proliferative inflammation, were formed. Cavity formation
was not recognized in animal tuberculosis, except for rabbits. Using rabbit models, Dr. Arthur
Dannenberg described the pathology of tuberculosis in detail [2, 3]. There are five stages: onset,
symbiosis, early stages of caseous necrosis, interplay of cell-mediated immunity and tissue
damaging delayed-type hypersensitivity, and liquefaction and cavity formation. In stage 1,
tubercle bacilli are usually destroyed or inhibited by the mature resident alveolar macrophages
that ingest them. If bacilli are not destroyed, they grow and eventually destroy the alveolar
macrophages. In stage 2, bacilli grow logarithmically within the immature nonactivated
macrophages. These macrophages enter a tubercle from the bloodstream. This stage is termed
symbiosis because bacilli multiply locally without apparent damage to the host, and macro‐
phages accumulate and divide. In stage 3, the stage at which caseous necrosis first occurs, the
number of viable bacilli becomes stationary because their growth is inhibited by the immune
response to tuberculin-like antigens released from bacilli. Stage 4 is the stage that usually
determines whether the disease becomes clinically apparent. Cell-mediated immunity plays a
major role in this situation. The cytotoxic delayed- type hypersensitivity immune response
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kills these macrophages, causing enlargement of the caseous center and progression of the
disease. If good cell-mediated immunity develops, a mantle of highly activated macrophages
surrounds the caseous necrosis. In stage 5, bacilli evade host defenses. When liquefaction of
the caseous center occurs, the bacilli multiply extracellularly, frequently attaining very large
numbers. The high local concentration of tuberculin-like products derived from these bacilli
causes a tissue-damaging delayed-type hypersensitivity response that erodes the bronchial
wall, forming a cavity.
A B
C D
Figure 1. Histologic appearance of tuberculosis A. Staining for acid‐fast bacilli, B. exudative stage, C. productive stage
with cavity formation (→), D. proliferative stage with a multinucleated giant cell.
2. Clinical manifestations
As the cellular processes occur, tuberculosis may develop differently in each patient, according
to the status of the patient’s immune system. Stages include latency, primary disease, primary
progressive disease, and extrapulmonary disease. Each stage has different clinical manifesta‐
tions [4]. M. tb organisms can be enclosed but are difficult to completely eliminate [5]. Persons
with latent tuberculosis have no signs or symptoms of the disease, do not feel sick, and are not
infectious [5]. However, viable bacilli can persist in the necrotic material for years or even a
lifetime [6], and if the immune system later becomes compromised, as it does in many critically
ill patients, the disease can be reactivated. Primary pulmonary tuberculosis is often asympto‐
matic. Although it essentially exists subclinically, some self-limiting findings might be noticed.
Associated paratracheal lymphadenopathy may occur because the bacilli spread from the
lungs through the lymphatic system. Active tuberculosis develops in only 5% to 10% of persons
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exposed to M. tb. Fig. 2 shows typical chest X-ray before (A) and after (B) chemotherapy.
Fatigue, malaise, weight loss, low-grade fever, night sweats, cough, sputum, are the main
symptoms. The sputum may also be streaked with blood. Hemoptysis can be due to destruc‐
tion of a patent vessel located in the wall of the cavity [7]. Extrapulmonary disease occurs in
more than 20% of patients. The most serious location is the central nervous system, where
infection may result in meningitis, which could be fatal in most cases. Another fatal form is
infection of the blood stream by mycobacteria, this form is called disseminated or military
tuberculosis. The most common extrapulmonary tuberculosis is lymphatic tuberculosis. Other
possible locations include bones, joints, pleura, and genitourinary system [4].
A B
Figure 2. Chest X‐ray of pulmonary tuberculosis and cured Tuberculosis A. before chemotherapy with rifampicin, iso‐
niazide, ethambutol and pyrazinamide, B. after chemotherapy. Apical shadow (dotted circle) disappears.
3. T cell activation against Mycobacterium tuberculosis
In human, a TB index case may infect a contact person through cough and expectoration,
so the lung is the primary route of infection and often the main tissue exhibiting TB. Infec‐
tious droplet nuclei are deposited in the alveolar spaces of the contact person where Myco‐
bacterium tuberculosis (M. tb) can be phagocytosed by alveolar macrophages, epithelial cells,
dendritic cells (DC) and neutrophils [8, 9]. Alveolar macrophages and DC are then believed
to transport M. tb to local lymph nodes where T cell activation occurs and expand. Activa‐
tion of the phagocytic host cell is much required to limit growth of M. tb; as in the absence
of activation, disease outcome is extremely poor. Effective phagocyte activation requires a
specific cellular response, as infected hosts lacking specific components of the acquired re‐
sponse have a poor outcome [10]. While acquired cellular protection is expressed rapidly
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following systemic challenge with M. tb, it is less rapid in the lung. Slow expression of pro‐
tection in the lung allows mycobacteria to grow and modulate the infection site. Until re‐
cently  it  has  not  been  clear  whether  the  slow  response  to  aerosol  delivery  of  bacteria
resulted from limited availability of antigen or inhibition of antigen-presentation by M. tb.
Several  studies  show that  the  first  T  cell  activation  occurs  in  the  draining lymph node
(DLN) of the lung 8–10 days following initial challenge. The activation of T cells correlated
temporally with the arrival of bacteria and availability of antigen in the DLN, however con‐
ditions for T cell activation were unique to the draining lymph nodes as the presence of an‐
tigen-producing bacteria in the lung and spleen did not result in initial activation of T cells
[11, 12]. While delivery of lipopolysaccharide (LPS) to the MTB-infected lung failed to ac‐
celerate T cell priming [11], increasing the bacterial dose did accelerate the response mod‐
estly suggesting that both antigen burden and refractory cells serve to slow the response.
So, protective memory cells will not become activated until they see antigen, i.e. more than
8 days post infection. Once T cells become activated they differentiate into effector T cells
that migrate to the lung. By day 14 of infection, when activated T cells first arrive in the
lung, bacteria are within alveolar macrophages, myeloid DC and neutrophils [11]. T cells
can recognize antigen within the mycobacterially-infected lung but the antigen presenta‐
tion is not optimal. It takes time for the protective T cells to reach sufficient numbers to
stop bacterial growth. T cells can be divided into two subsets, Th1 and Th2, on the basis of
the cytokines they produce. In tuberculosis, Th1 plays a major role in defense against tuber‐
culosis. Th1 cells suppress Th2 cells. CD4 + T cells have unambiguously been identified as
the most important lymphocyte subset for mediating protection.CD4 T lymphocytes differ‐
entiate in the peripheral tissues to adopt a variety of fates such as the Th-1 cells, which pro‐
duce  interferon (IFN)-γ  to  down-regulate  Th2  responses  and Th-2  cells,  which  produce
interleukin  (IL)-4.  CD8  T  lymphocytes  produce  predominantly  IFN-γ.  Though  CD4  re‐
sponse is greater than the CD8 response, the latter can provide protection in the absence of
CD4 help [13]. During active TB there is a local pulmonary immune response characterized
by α/β T cells and strongly enhanced M. tuberculosis antigen-specific Th1 responses, with
large amounts of locally secreted IFN-γ [14].
4. Animal models of tuberculosis
A wide variety of animal models have been used to test new vaccines and drugs [15]. Mice can
harbor high numbers of M. tb within lung tissue without showing clinical signs [16]. Mice do
not cough nor form cavitary lesions, making them a poor model for transmission studies [17].
Fibrous capsules are not observed histologically, which can affect the validity of antibiotic
studies, as M. tb would be more easily accessed by drugs in the mouse lung. In addition,
because of their short life span, mice are poor models for the study of latent infection. Rat TB
also showed similar pathophysiology to murine TB [31]. Guinea pigs develop robust DTH
response to mycobacterial antigens and, after infection with M. tb, reproduce many of the
aspects of human infection, such as caseous and mineralized granulomas, primary and
hemato-genous pulmonary lesions, fibrous capsule formation, and dissemination [19],
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however, pulmonary lesions in guinea pig contain a high proportion of granulocytes, partic‐
ularly eosmophils, which are not common features of human disease [20]. The rabbit is the
only common laboratory animal in which the disease closely resembles the typical chronic
cavitary type found in the majority of human beings [21, 22]. Rabbits infected with M. tb mount
a moderate DTH response and form caseous granulomas and cavitary lesions [23-25]. Rabbits,
including currently available inbred strains, are relatively resistant to M. tb, however, requiring
the inhalation of 500 to 3000 bacilli to form one grossly visible tubercle at 5 weeks postinfection
[23]. Most rabbits will also overcome disease completely, with few culturable bacilli [24]. This
model is useful in the study of latent or paucibacillary TB states, however, without the use of
antibiotics as in the Cornell model. Rabbits do need to be experimentally immunosuppressed
as they will not spontaneously reativate disease [26]. There are minimal immune reagents,
however, for this model, and the larger size of rabbits makes them more costly to use. There
are inbred strains of rabbits, such as the Lurie and Thorbecke rabbits, which are more suscep‐
tible to M. tb infection. This susceptibility has been linked to suppressed macrophage antimy‐
cobacterial activity, decreased MHC Class 2 expression, and impaired development of type 4
hypersensitivity [27]. Other animal models, such as nonhuman primates, which are susceptible
to M. tb and full spectrum of granuloma types can be observed [28], have not been widely used.
Using mycobacterial inoculation into trachea, at necropsy, all unvaccinated monkeys (Macaca
fascicularis and Macaca mulatta) exhibited extensive bilateral lung pathology characterized by
the presence of multiple granulomas. These granulomas exhibited conglomeration to larger
caseous areas, especially in the hilar region [55].
5. Alveolar macrophages in tuberculosis
When tubercle bacilli reach alveoli, they are phagocytosed by resident alveolar macrophages.
Though tubercle bacilli are killed byalveolar macrophages, tubercle bacilli can also kill
macrophages through apoptosis. What is the fate of tubercle bacilli once they enter the
phagosomes of macrophages? Alveolar macrophages of aerially infected guinea pigs were
collected by bronchoalveolar lavage. At 12 days after infection, one out of 10,000 alveolar
macrophages of various sizes contained many tubercle bacilli [31]. This indicates that certain
alveolar macrophages permit M. tuberculosis to replicate in the phagosomes, although most
of tubercle bacilli are killed by activated alveolar macrophages. It will be of great interest to
examine the survival mechanism of M. tuberculosis at the single-cell level, but we still do not
know why macrophages targeted by tubercle bacilli cannot kill the bacilli.
IFN-γ knockout mice were infected with avirulent H37Ra or BCG Pasteur, multinucleated
giant cells were recognized in the granulomatous lesions. The lesions also contained tubercle
bacilli and consisted of multinucleated cell clusters, being immunopositive with anti-Mac-3
antibody. The alveolar macrophages were transformed into multinucleated ginat cells. We
subsequently infected various cytokine-konockout mice with M. tb, but no Langerhans’
multinucleated giant cells were recognized in the granulomas. Therefore, it seems that
formation of multinucleated giant cells requires optimal combinations and concentrations of
various cytokines, and the level of IFN-γ, at least, has to be significantly low.
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6. Roles of cytokines, neutrophils, NK cells, NKT cells and γδT cells
IFN-γ and TNF have long been implicated as regulators of T cell responses in mycobacterial
disease [29]. The technique of gene targeting (knockout) has swept through biomedical
research. IFN-γ, TNF-α, IRF-1, NF-IL6, NF-κB p50, STAT 1 and STAT 4 knockout mice
succumbed to M. tuberculosis infection over time. There appears to be a cytokine and tran‐
scription factor hierarchy in experimental tuberculosis. The results indicate that these mole‐
cules play major roles in defense against the disease, IFN-γ and TNF-α being the leading
players in this respect [30].
The role of neutrophils in the development of tuberculosis remained unknown for a long time.
We utilized LPS-induced transient neutrophilia in the lungs [31]. LPS (50μg/ml) was admin‐
istered intratracheally to male Fischer rats, which were then infected with M. tuberculosis via
an airborne route. Intratracheal injection of LPS significantly blocked the development of
pulmonary granulomas and significantly reduced the number of pulmonary colony-forming
units (CFU). Treatment with amphotericin B (an LPS inhibitor) or neutralizing anti-rat
neutrophil antibody reversed the development of pulmonary lesions. LPS-induced transient
neutrophilia prevented early mycobacterial infection. The timing of LPS administration was
important. When given intratracheally at least 10 days after aerial infection, LPS did not
prevent the development of tuberculosis. Neutrophils obtained by bronchoalveolar lavage
killed M. tuberculosis bacilli. These results indicate clearly that neutrophils participate actively
in defense against early-phase tuberculosis.
Natural killer (NK) cells are innate lymphocytes which are a first line of defense against
infection. NK cells can kill autologous infected cells without prior sensitization, and are
believed to play a pivotal role in innate immunity to microbial pathogens. In mouse model,
NK cells are activated and produce IFN-γ during the early response to pulmonary tuberculosis
[31] and NK cell-produced IFN-γ regulates the anti-mycobacterial resistance mediated by
neutrophils [32]. However animal models do not give a clear answer to whether NK cells is
important in M. tb infection in vivo. Depletion of NK cells had no effect on bacterial replication
in the lung of immunocompetent mice [33], suggesting that NK cells may be redundant in the
presence of intact adaptive immunity. Surprisingly, IFN-γ knockout mice, which are impaired
in their ability to clear mycobacteria, cleared them as effectively as wild-type mice when NK
cells were depleted, suggesting that NK cells can inhibit protective immunity [34].
Human NK cells use the NKp46, the natural cytotoxicity receptors (NCRs) and NKG2D
receptors to lyse M. tuberculosis-infected monocytes and alveolar macrophages [35], through
damage of infected cells and secretion of cytokines, such as IFN-γ [36]. Inhibitory receptors of
NK cells include killer immunoglobulin-like receptors (KIRs) and the NKG2A:CD94 dimer
and NK cell activation can also be triggered by loss of inhibitory ligands from the cell surface.
In addition, NK cells can also be activated by cytokines, including type I interferons, IL-12 and
IL-18. NK cells are a potent and early source of cytokines, particularly IFN- γ, but they can also
produce Th2-associated cytokines, such as IL-5 and IL-13, and the regulatory cytokine IL-10
[37]. NK cell NKp46 expression and cytotoxicity are reduced in freshly isolated peripheral
blood mononuclear cells (PBMCs) from tuberculosis patients, which may be attributable to
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suppression by monocytes and IL-10. Recent studies have found that NK cells produce IL-22
[38], which was induced by IL-15 and DAP-10, an adaptor protein that is known to be involved
in NK cell activation, in response to M. tuberculosis. Rohan Dhiman et al. also found that IL-22
can restrict growth of M. tuberculosis in macrophages by enhancing phagolysosomal fusion
[39]. Nonetheless to fully understand the importance of NK cells in M. tb infection it may be
necessary to differentiate their contributions at different stages of disease.
Certain T subsets, such as NKT cells and γδ T cells, have features of innate immune cells
including a partially activated phenotype, a rapid response following detection of infected
cells, and the modulation of other cell types. Together with NK cells, these cell subsets are
functionally defined as innate lymphocytes.CD1d-restricted invariant NKT (iNKT) cells are a
conserved subset of T cells that express an invariant T cell receptor (TCR) α chain (Vα24-Jα18
in humans, and Vα14-Jα18 in mice) paired with TCR β chains encoded by one or a few Vβ
gene segments (Vβ11 in humans, and predominantly Vβ2, 7 and 8 in mice). These cells show
different phenotypes and functions [40].Many iNKT cells are CD4+, and they have been mainly
associated with the induction of Th2 cytokines such as IL-4, IL-5, IL-13. This subset is believed
to play a prominent role in suppression of autoimmune or chronic inflammatory diseases, and
in promoting allergic conditions such as asthma. Few iNKT cells are CD8+, and most of those
express only the CD8α subunit, which means that they likely express only CD8αα homodim‐
ers. An additional fraction of iNKT cells are negative for both CD4 and CD8 (DN T cells). They
have been found to produce predominantly IFN-γ and other Th1-associated cytokines. Studies
of human iNKT cells have shown that they have the ability to kill M. tuberculosis organisms
within infected macrophages, possibly through their production of the peptide granulysin [41].
Jin S. Im et al. [42] found that the percentages of iNKT cells among total circulating T cells in
TB patients were not significantly different compared to those in healthy controls. However,
TB patients showed a selective reduction of the proinflammatory CD4−CD8− (DN) iNKT cells
with a proportionate increase in the CD4+ iNKT cells. The mouse model of tuberculosis has
been used by Sada-Ovalle et al to find that iNKT cells have a direct bactericidal effect on M.
tuberculosis, and protect mice against aerosol M.TB infection [43]. Their activation requires
CD1d expression by infected macrophages as well as IL-12 and IL-18. In addition, pharmaco‐
logical activation of iNKT cells with the synthetic ligand aGalCer often enhances host resist‐
ance to infection. iNKT cell use several mechanisms to modify host immunity. These include
induction of DC maturation, secondary activation of effector cells (NK cells) or recruitment of
inflammatory cells to the site of infection [44, 45]. Thus, by being an early producer of IFN-γ
and suppressing intracellular bacterial growth, iNKT cells function as an important part of the
early immune response against M. tb that affect both the innate and the adaptive arms of the
immune response.
Antigen-specific γ/δ T cells represent an early innate defense that may play a role in antimy‐
cobacterial immunity. Studies done in humans and animal models have demonstrated
complex patterns of γ/δ T cell immune responses during early mycobacterial infections and
chronic TB. Like α/β T lymphocytes, γ/δ T cells carry antigen TCR that vary in the physical
properties of their ligand-binding sites. γ/δ T cells are frequently activated by a variety of
pathogens including M. tb [46]. Mice lacking γ/δ T cells succumb more rapidly than control
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mice following intravenous challenge with virulent M. tb; however, such a difference has not
been observed following infection by the aerosol route. γ/δ T cells constitute a whole system
of functionally specialized subsets that have been implicated in the innate responses against
tumors and pathogens, the regulation of immune responses, cell recruitment and activation,
and tissue repair [47]. Human alveolar macrophages and monocytes can serve as antigen
presentation cells (APCs) for γ/δ T cells. Furthermore, the predominance of Vγ9Vδ2 T cells in
TB disease has been confirmed [48]. When MTB-activated CD4+ and γ/δ T cells from healthy
tuberculin-positive donors were analyzed for cytokine production in response to MTB-
infected monocytes, both groups secreted large amounts of IFN-γ [49]. Previous studies have
also demonstrated an increased proliferative activity of Vγ9Vδ2 T cells from patients with TB
[50], but reduced production of IFN-γ, compared with that of healthy tuberculin-positive
donors [51]. Additionally, Dieli et al. reported that decrease of Vγ9Vδ2 T cell effector functions
involves not only IFN-γ production but also expression of granulysin [52]. Fig. 3 shows
interaction of cells and cytokines involved in tuberculosis.
neutrophil
Figure 3. Cytokine and cellular network in tuberculosis +. Production of cytokine, ‐. No production of cytokine.
7. Conclusion
Tuberculosis is an international public health problem. It is becoming evident that M. tb
infection is a dynamic state with a wide spectrum of pathology. An improved understanding
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of the immunopathogenesis of TB can facilitate the design of effective vaccines, new drug
candidates and evaluation of their efficacy [53]. Understanding latent tuberculosis can also be
the key to improve diagnostic and novel treatment strategies [54].
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